Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Decarolis

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Clinical and Translational Radiation Oncology|May 23, 2022
Radiotherapy for pediatric adrenocortical carcinoma - Review of the literatureVerena Wiegering, Maria Riedmeier, Lester D R Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patientsEsther M van Wezel, Boris Decarolis, Janine Stutterheim, et al.
Pediatric Blood & Cancer|May 6, 2015
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastomaEsther M van Wezel, Janine Stutterheim, Florentien Vree, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 25, 2024
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation studyLieke M J van Zogchel, Boris Decarolis, Esther M van Wezel, et al.
JCO Precision Oncology|May 26, 2021
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease PanelEsther M van Wezel, Lieke M J van Zogchel, Jalenka van Wijk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Clinical and Translational Radiation Oncology|May 23, 2022
Radiotherapy for pediatric adrenocortical carcinoma - Review of the literatureVerena Wiegering, Maria Riedmeier, Lester D R Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patientsEsther M van Wezel, Boris Decarolis, Janine Stutterheim, et al.
Pediatric Blood & Cancer|May 6, 2015
Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastomaEsther M van Wezel, Janine Stutterheim, Florentien Vree, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 25, 2024
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation studyLieke M J van Zogchel, Boris Decarolis, Esther M van Wezel, et al.
JCO Precision Oncology|May 26, 2021
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease PanelEsther M van Wezel, Lieke M J van Zogchel, Jalenka van Wijk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Pageof 2